Intervention not reported
Fear of falling scores at 6 months Assessed by Short Falls Efficacy Scale‐International · older adults (aged 60 and over) with irreversible visual impairment
The intervention showed no clear difference in fear of falling scores at 6 months Assessed by Short Falls Efficacy… (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life at 6 months Assessed by 12‐Item Short Form Health Survey · older adults (aged 60 and over) with irreversible visual impairment
The intervention showed no clear difference in quality of life at 6 months Assessed by 12‐Item Short Form Health… (low certainty).
1 finding from 1 review
Intervention not reported
Physical activity at 6 months Assessed by self‐reported physical activity · older adults (aged 60 and over) with irreversible visual impairment
The intervention showed no clear difference in physical activity at 6 months Assessed by self‐reported physical… (low certainty).
1 finding from 1 review
Intervention not reported
Fall measures · older adults (aged 60 and over) with irreversible visual impairment
The intervention may leads to lower fall measures (low certainty).
1 finding from 1 review
Intervention not reported
Fear of falling scores at 6 months Assessed by Short Falls Efficacy Scale‐International · older adults (aged 60 and over) with irreversible visual impairment
The intervention showed no clear difference in fear of falling scores at 6 months Assessed by Short Falls Efficacy… (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life at 6 months Assessed by European Quality of Life‐15 · older adults (aged 60 and over) with irreversible visual impairment
The intervention showed no clear difference in quality of life at 6 months Assessed by European Quality of Life‐15 (low certainty).
1 finding from 1 review
Gain of 15 letters or more of visual acuity at 6 months · macular oedema secondary to branch retinal vein occlusion
Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity at 6 months compared with sham (moderate certainty).
1 finding from 1 review
QoL · people with BRVO
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BCVA: gain of 15 or more ETDRS letters · people with BRVO
Anti‐VEGF leads to higher gain of 15 letters or more of visual acuity compared with steroid (high certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with BRVO
1 finding from 1 review
Central retinal thickness μm (CRT) change at 1 year The aim of treatment is to reduce central retinal thickness so thinner is better. · people with BRVO
1 finding from 1 review
Adverse outcomes at any time point · people with BRVO
Anti‐VEGF probably leads to lower adverse outcomes at any time point compared with steroid (moderate certainty).
1 finding from 1 review
QoL · people with BRVO
1 finding from 1 review
Visual acuity · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review
Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review
Adverse outcomes at any time point · macular oedema secondary to branch retinal vein occlusion
It is very uncertain whether anti‐VEGF changes adverse outcomes at any time point compared with sham (very low certainty).
1 finding from 1 review
QoL · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review
BCVA: gain of 15 or more ETDRS letters · people with BRVO
Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity compared with laser (moderate certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with BRVO
1 finding from 1 review
Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) · people with BRVO
1 finding from 1 review